Higher levels of cCASP8 were associated with better DSS among the patients with lymph node metastases, suggesting that inactivating mutations in CASP8 might be linked to a poorer clinical outcome. This evidence concerns the gene CASP8 and metastatic malignant neoplasm in the lymph nodes.